AI assistant
Teva Pharmaceutical Industries Ltd. — Regulatory Filings 2013
Jun 12, 2013
7082_ffr_2013-06-12_c269bd8f-96c5-47d0-b35b-c2b6441ad4a7.zip
Regulatory Filings
Open in viewerOpens in your device viewer
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
June 12, 2013
Commission File Number: 0-16174 End Cover Page Header Cover Page Registrant
| Teva Pharmaceutical Industries Ltd. |
|---|
| (Translation of registrants name into English) |
| Israel |
| (Jurisdiction of incorporation or organization) |
| 5 Basel Street, P.O. Box 3190 Petach Tikva 49131 Israel |
| (Address of principal executive office) |
End Cover Page Registrant Checkboxes Page
| Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: [ x ] Form 20-F [ ] Form 40-F |
|---|
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ] |
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ] |
| Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: [ ] Yes [ x ] No |
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): n/a
End Checkboxes Page HR Page Break
End HR Page Break Report Page End Report Page Page Break
Page Break
End Page Break Signatures Page Header SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
End Signatures Page Header Signatures Page Details
| By: | Teva Pharmaceutical Industries Ltd. — Eyal Desheh |
|---|---|
| Name: | Eyal Desheh |
| Title: | Chief Financial Officer |
End Signatures Page Details HR Page Break
End HR Page Break Exhibit Index Header Page EXHIBIT INDEX
| Exhibit No. | Description |
|---|---|
| 99.1 | Teva Reaches Settlement Agreement with Pfizer and Nycomed Regarding Generic Protonix® (Pantoprazole) Tablets |
End ExhibitIndexFooter HR Page Break
End HR Page Break HTML Footer Page